原发性肝癌TACE前后sICAM-1的动态变化及其意义
|
摘要
目的检测原发性肝癌患者经肝动脉插管化疗栓塞(TACE)前后血清细胞间黏附分子1(sICAM-1)的动态变化,探讨sICAM-1与肿瘤活性的关系。方法运用酶联免疫吸附试验方法测定36例原发性肝癌患者第1次TACE术前、术后3d、7d及术后1个月血清ICAM-1的水平。结果TACE术前原发性肝癌患者sICAM-1的水平(647.94±95.69)μg/L明显高于健康对照组sICAM-1的水平(201.07±68.81)μg/L,差异有统计学意义(P＜0.01),术前sICAM-1水平在不同甲胎蛋白含量各组间无明显差异(P＞0.05)。术后3d sICAM-1的水平(567.85±99.79)μg/L与术后7d sICAM-1的水平(542.84±89.94)μg/L较术前显著下降(P＜0.01),并且术后7d低于3d的sICAM-1水平(P=0.022＜0.05),无门脉癌栓组术后1个月sICAM-1水平与术前相比差异有统计学意义(P＜0.01)。并且术后1个月肿瘤体积减小比例与sICAM-1下降幅度成正比,线性回归分析(r=0.77,P＜0.05)。结论:sICAM-1水平的变化与肿瘤活性密切相关,对判断原发性肝癌,尤其是AFP阴性的患者再次TACE的指征及评价TACE疗效方面有一定的价值。
Objective To observe the changes of serum soluble intercellular adhesion molecule-1 (slCAM-1) in patients with hepatocellular carcinoma(HCC) before and after transcatheter arterial chemoembolization (TACE) and to identify clinical significance of serum sICAM-1 in estimating the activity of the tumour. Method Serum sICAM-1 in patients with HCC were detected by ELISA before the first TACE, 3 days after TACE , 7 days after TACE and 1 month after TACE respectively. Results Compared with control group (201.07±68.81)μg/L, the level of serum sICAM-1 in patients with HCC before the first TACE (647.94±95.69)μg/L increased significantly (P<0.01) .The level of serum sICAM-1 had not significant difference in patients with HCC before the first TACE between different AFP groups. The level of serum sICAM-1 declined remarkably 3 after TACE, 7 days after TACE(567.85±99.79μg/L, 542.84±89.94μg/L, respectively) , and the level of serum sIC AM-1 of 7 days is lower than the level of serum sICAM-1 of 3 days after TACE (P =0.022<0.05) . The level of serum sICAM-1 had significant difference between 1 month after TACE and before TACE in patients of HCC without portal vein embolus(P<0.01 ) , and the diminished extent of the tumor of 1 month after TACE was directly correlated with the corresponding descent of slCAM-1 (r=0.77, P <0.01).Conclusion It can be concluded that slCAM-1 levels in patients with primary liver cancer were closely related to the activity of the tumour .The changes of sICAM-1 are valuable in estimating the prognosis after TACE and evaluating the indication of re-TACE treatment in patients with primary liver cancer especially those AFP are negative.
Objective To observe the changes of serum soluble intercellular adhesion molecule-1 (slCAM-1) in patients with hepatocellular carcinoma(HCC) before and after transcatheter arterial chemoembolization (TACE) and to identify clinical significance of serum sICAM-1 in estimating the activity of the tumour. Method Serum sICAM-1 in patients with HCC were detected by ELISA before the first TACE, 3 days after TACE , 7 days after TACE and 1 month after TACE respectively. Results Compared with control group (201.07±68.81)μg/L, the level of serum sICAM-1 in patients with HCC before the first TACE (647.94±95.69)μg/L increased significantly (P<0.01) .The level of serum sICAM-1 had not significant difference in patients with HCC before the first TACE between different AFP groups. The level of serum sICAM-1 declined remarkably 3 after TACE, 7 days after TACE(567.85±99.79μg/L, 542.84±89.94μg/L, respectively) , and the level of serum sIC AM-1 of 7 days is lower than the level of serum sICAM-1 of 3 days after TACE (P =0.022<0.05) . The level of serum sICAM-1 had significant difference between 1 month after TACE and before TACE in patients of HCC without portal vein embolus(P<0.01 ) , and the diminished extent of the tumor of 1 month after TACE was directly correlated with the corresponding descent of slCAM-1 (r=0.77, P <0.01).Conclusion It can be concluded that slCAM-1 levels in patients with primary liver cancer were closely related to the activity of the tumour .The changes of sICAM-1 are valuable in estimating the prognosis after TACE and evaluating the indication of re-TACE treatment in patients with primary liver cancer especially those AFP are negative.
引文
[1]Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer JClin,2005,55(2):74
[2]吴孟超,程树群.原发性肝癌外科治疗中应注意的问题[J].中华肝胆外科杂志:2002,8(3):131-132
[3]Okusaki T,Odada S,Ueno H,et al.Evaluation of therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma[J].Oncology,2000,58(4):293-299
[4]刘嵘,王建华,颜志平等.原发性肝癌综合介入治疗后存活5年以上56例患者临床分析[J].介入放射学杂志,2007,16(3):155-158
[5]Liou TC,Sbih SC,Kao CR,et al.Pulmonary metastasis ofhepatocellular carcinoma associated with transarterial chemoembohzation[J].Hepatology,1995,23(5):563-568.
[6]汪盛齐,杨小庆,邓钢等.磁共振扩散加权成像评价肝癌介入术后疗效的临床及动物实验研究[J].东南大学学报,2006,25(5):357-361
[7]罗葆明,段红艳,文艳玲等.低机械指数谐波超声造影评估肝细胞癌介入治疗效果[J].中华医学超声杂志,2006,3(4):234-236
[8]中国抗癌协会肝癌专生委员会.原发性肝癌的临床诊断与分期标准[J].肿瘤防治研究,2002,29(1):83
[9]张闽峰,孟加榕,郑瑞丹,等.肝癌及肝硬化组织中ICAM-1和Topo Ⅱ的表达[J].临床与实验病理学杂志,2004,20(4):420-422.
[10]Jing Xu,Ming Hui Mei,Si En Zeng,et al.Expressions of ICAM-1 and its mRNA in sera andtissues of patients with hepatocellular carcinoma[J].World J Gastroentero,2001,7(1):120-125
[11]Harada T,Kawaminami H,Miura NN.cell to cell contact though ICAM-1-TNF-alpha synergistically contributes to GM-CSF and subsequent cytokine synthesis in DBA/2 mice induced by 1,3-beta-D-Glucan SCG[J]Interf cytok Res,2006,26(4):235-247
[12]Jing-Jing Sun,Xin-Da Zhou,Yin-Kun Liu.Invasion and metastasis of liver cancer:expression of intercellular adhesion molecule 1[J].Cancer Res Clin Oncol,1999,125(5):28-34
[13]熊枝繁,刘菊,曹仕琼等.肝细胞肝癌组织ICAM-1及血清sICAM-1,水平变化的临床意义[J].实用医学杂志,2006,22(3):274-276
[14]Kim R,Tana K,Emic M.cancer cell immune escape and tumer progression by exploitation of anti-inflanmmatory and pro-inflammatory responses[J].Cancer Biol Ther,2005,4(9):924-933
[15]主余华,傅丽娜,孙成刚等.细胞间粘附分子-1在原发性肝癌的检测及意义[J].临床肝胆病杂志,2002,18(3):154-156
[16]Toshihi S,Tom T.Comhination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatoceUularcarcinama[J].Cancer,2000,89(6):1245-1252
[17]吴孟超.原发性肝癌的诊断和治疗进展[J].中华外科杂志,1998,36(9):515-517.
[18]邵国良,王建华,周康荣等.肝癌化疗栓塞术后残癌组织微血管密度及血管内皮细胞生长因子表达的研究[J].中华肝胆外科杂志,2002,6(3):170-173
[19]Xin Li,Gan-Sheng Feng,Chuan-Sheng Zheng,et al.Expression of plasma vascular endothelial growth factor in patientswith hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level[J].World J Gastroenterol,2004,10(19):2878-2882
[20]向昕,刘志伟,顾万清等.TACE后肝癌微血管密度及血管内皮生长因子的表达与二期手术的相关性研究[J].中华肝胆外科杂志,2004,6(6):389-391
[21]Jing Chen,Hua Wu,Deyan Han.Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer [J].Cancer Letters 2006,231:169-175
[22]余永胜,侯英勇,刘永忠等.慢性乙型肝炎和肝癌患者ICAM—1表达及细胞因子对其调节作用的观察[J].临床内科杂志,2000,17(6):364-365
[23]Judith K Michelson,Gilbert Kukielka,J Stanley Bravenec,et al.Differential Expression and Release of CD54 Induced by Cytokines[J].Hepatology,1995,22(3):866-875
[1]Jing Xu,Ming Hui Mei,Si En Zeng,et al.Expressions of ICAM-1 and its mRNA in sera andtissues of patients with hepatocellular carcinoma[J].World J Gastroentero,2001,7(1):120-125
[2]杨晓红,唐恩洁,任碧轩.重组P53基因转染的肝癌细胞ICAM-1分子的表达[J].细胞与分子免疫学杂志,2004,20(6):674-674
[3]张雪萍,刘新波,任永功,等.NF-kappaB对ICAM-1表达的调节作用[J].中国临床药理学与治疗学,2006,11(1):55-58
[4]Jing Chen,Hua Wu,Deyan Han.Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer [J].Cancer Letters,2006,231(2):169-175
[5]Sun JJ,Zhou XD,Liu YK,et al.Inhibitory effects of synthetic beta peptide on invasion and metastasis of liver cancer[J].Journal of cancer research and clinical oncology,2000,126(10):595-600.
[6]刘菊,熊枝繁.肝癌组织中ICAM-1的表达和意义[J].胃肠病学和肝病学杂志,2005,10(4):515-517
[7]韦长元,李挺,刘剑仑等.Ⅰ型细胞间粘附分子与肝癌侵袭转移的关系[J].肝胆外科杂志,2001,9(1):57-58
[8]葛谭.原发性肝癌患者手术前后血清SICAM-1、VEGF水平检测的临床意义[J].放射免疫学杂志,2005,18(1):73-74.
[9]Jing-Jing Sun,Xin-Da Zhou,Yin-Kun Liu.Invasion and metastasis of liver cancer:expression of intercellular adhesion molecule 1[J].J Cancer Res Clin Oncol,1999,125(1):28-34
[10]主余华,傅丽娜,孙成刚等.细胞间粘附分子—1在原发性肝癌的检测及意义[J].临床肝胆病杂志,2002,18(3):154-156
[11]熊枝繁,刘菊,曹仕琼等.肝细胞肝癌组织ICAM—1及血清sICAM—1水平变化的临床意义[J].实用医学杂志,2006,22(3):274-276
[12]Harada T,Kawaminami H,Miura NN.cell to cell contact though ICAM-1-TNF-alpha synergistically contributes to GM-CSF and subsequent cytokine synthesis in DBA/2 mice induced by 1,3-beta-D-Glucan SCG[J].J Interf cytok Res,2006,26(4):235-247
[13]朱争艳,杜智,王毅军等.CD15、CD44v6和CD54检测与肝癌复发转移的关系研究[J].临床肝胆病杂志,2001,17(4):244-245
[14]Kim R,Tana K,Emic M.cancer cell immune escape and turner progression by exploitation of anti-inflanmmatory and pro-inflammatory responses[J].Cancer Biol Ther,2005,4(9):924-933
[2]吴孟超,程树群.原发性肝癌外科治疗中应注意的问题[J].中华肝胆外科杂志:2002,8(3):131-132
[3]Okusaki T,Odada S,Ueno H,et al.Evaluation of therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma[J].Oncology,2000,58(4):293-299
[4]刘嵘,王建华,颜志平等.原发性肝癌综合介入治疗后存活5年以上56例患者临床分析[J].介入放射学杂志,2007,16(3):155-158
[5]Liou TC,Sbih SC,Kao CR,et al.Pulmonary metastasis ofhepatocellular carcinoma associated with transarterial chemoembohzation[J].Hepatology,1995,23(5):563-568.
[6]汪盛齐,杨小庆,邓钢等.磁共振扩散加权成像评价肝癌介入术后疗效的临床及动物实验研究[J].东南大学学报,2006,25(5):357-361
[7]罗葆明,段红艳,文艳玲等.低机械指数谐波超声造影评估肝细胞癌介入治疗效果[J].中华医学超声杂志,2006,3(4):234-236
[8]中国抗癌协会肝癌专生委员会.原发性肝癌的临床诊断与分期标准[J].肿瘤防治研究,2002,29(1):83
[9]张闽峰,孟加榕,郑瑞丹,等.肝癌及肝硬化组织中ICAM-1和Topo Ⅱ的表达[J].临床与实验病理学杂志,2004,20(4):420-422.
[10]Jing Xu,Ming Hui Mei,Si En Zeng,et al.Expressions of ICAM-1 and its mRNA in sera andtissues of patients with hepatocellular carcinoma[J].World J Gastroentero,2001,7(1):120-125
[11]Harada T,Kawaminami H,Miura NN.cell to cell contact though ICAM-1-TNF-alpha synergistically contributes to GM-CSF and subsequent cytokine synthesis in DBA/2 mice induced by 1,3-beta-D-Glucan SCG[J]Interf cytok Res,2006,26(4):235-247
[12]Jing-Jing Sun,Xin-Da Zhou,Yin-Kun Liu.Invasion and metastasis of liver cancer:expression of intercellular adhesion molecule 1[J].Cancer Res Clin Oncol,1999,125(5):28-34
[13]熊枝繁,刘菊,曹仕琼等.肝细胞肝癌组织ICAM-1及血清sICAM-1,水平变化的临床意义[J].实用医学杂志,2006,22(3):274-276
[14]Kim R,Tana K,Emic M.cancer cell immune escape and tumer progression by exploitation of anti-inflanmmatory and pro-inflammatory responses[J].Cancer Biol Ther,2005,4(9):924-933
[15]主余华,傅丽娜,孙成刚等.细胞间粘附分子-1在原发性肝癌的检测及意义[J].临床肝胆病杂志,2002,18(3):154-156
[16]Toshihi S,Tom T.Comhination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatoceUularcarcinama[J].Cancer,2000,89(6):1245-1252
[17]吴孟超.原发性肝癌的诊断和治疗进展[J].中华外科杂志,1998,36(9):515-517.
[18]邵国良,王建华,周康荣等.肝癌化疗栓塞术后残癌组织微血管密度及血管内皮细胞生长因子表达的研究[J].中华肝胆外科杂志,2002,6(3):170-173
[19]Xin Li,Gan-Sheng Feng,Chuan-Sheng Zheng,et al.Expression of plasma vascular endothelial growth factor in patientswith hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level[J].World J Gastroenterol,2004,10(19):2878-2882
[20]向昕,刘志伟,顾万清等.TACE后肝癌微血管密度及血管内皮生长因子的表达与二期手术的相关性研究[J].中华肝胆外科杂志,2004,6(6):389-391
[21]Jing Chen,Hua Wu,Deyan Han.Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer [J].Cancer Letters 2006,231:169-175
[22]余永胜,侯英勇,刘永忠等.慢性乙型肝炎和肝癌患者ICAM—1表达及细胞因子对其调节作用的观察[J].临床内科杂志,2000,17(6):364-365
[23]Judith K Michelson,Gilbert Kukielka,J Stanley Bravenec,et al.Differential Expression and Release of CD54 Induced by Cytokines[J].Hepatology,1995,22(3):866-875
[1]Jing Xu,Ming Hui Mei,Si En Zeng,et al.Expressions of ICAM-1 and its mRNA in sera andtissues of patients with hepatocellular carcinoma[J].World J Gastroentero,2001,7(1):120-125
[2]杨晓红,唐恩洁,任碧轩.重组P53基因转染的肝癌细胞ICAM-1分子的表达[J].细胞与分子免疫学杂志,2004,20(6):674-674
[3]张雪萍,刘新波,任永功,等.NF-kappaB对ICAM-1表达的调节作用[J].中国临床药理学与治疗学,2006,11(1):55-58
[4]Jing Chen,Hua Wu,Deyan Han.Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer [J].Cancer Letters,2006,231(2):169-175
[5]Sun JJ,Zhou XD,Liu YK,et al.Inhibitory effects of synthetic beta peptide on invasion and metastasis of liver cancer[J].Journal of cancer research and clinical oncology,2000,126(10):595-600.
[6]刘菊,熊枝繁.肝癌组织中ICAM-1的表达和意义[J].胃肠病学和肝病学杂志,2005,10(4):515-517
[7]韦长元,李挺,刘剑仑等.Ⅰ型细胞间粘附分子与肝癌侵袭转移的关系[J].肝胆外科杂志,2001,9(1):57-58
[8]葛谭.原发性肝癌患者手术前后血清SICAM-1、VEGF水平检测的临床意义[J].放射免疫学杂志,2005,18(1):73-74.
[9]Jing-Jing Sun,Xin-Da Zhou,Yin-Kun Liu.Invasion and metastasis of liver cancer:expression of intercellular adhesion molecule 1[J].J Cancer Res Clin Oncol,1999,125(1):28-34
[10]主余华,傅丽娜,孙成刚等.细胞间粘附分子—1在原发性肝癌的检测及意义[J].临床肝胆病杂志,2002,18(3):154-156
[11]熊枝繁,刘菊,曹仕琼等.肝细胞肝癌组织ICAM—1及血清sICAM—1水平变化的临床意义[J].实用医学杂志,2006,22(3):274-276
[12]Harada T,Kawaminami H,Miura NN.cell to cell contact though ICAM-1-TNF-alpha synergistically contributes to GM-CSF and subsequent cytokine synthesis in DBA/2 mice induced by 1,3-beta-D-Glucan SCG[J].J Interf cytok Res,2006,26(4):235-247
[13]朱争艳,杜智,王毅军等.CD15、CD44v6和CD54检测与肝癌复发转移的关系研究[J].临床肝胆病杂志,2001,17(4):244-245
[14]Kim R,Tana K,Emic M.cancer cell immune escape and turner progression by exploitation of anti-inflanmmatory and pro-inflammatory responses[J].Cancer Biol Ther,2005,4(9):924-933